All Articles

After more than 4 years of follow-up, the addition of daratumumab to lenalidomide and dexamethasone (D-Rd) continues to significantly improve progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, according to an update of the phase 3 POLLUX study. Patients on D-Rd also demonstrated deeper responses than patients who received lenalidomide and dexamethasone (Rd) alone.

In patients with newly diagnosed multiple myeloma, treatment with weekly daratumumab plus carfilzomib, lenalidomide, and dexamethasone (KRd) resulted in an “unprecedented” minimal residual disease (MRD) negativity rate of 77% without stem cell transplantation.

Payers and hospital systems can benefit tremendously through enhanced patient experience, clinical outcomes, and return on investment that navigation programs provide.

Most people have heard of palliative care, but few truly know the meaning. Palliative care is related to, but not the same as, hospice care.

In the United States, navigation is now an established part of the healthcare system. But in other countries it is still a brand-new concept, according to Nancy Peña, OPN-CG, Founder and Director of Navegación de Pacientes Internacional (NPI) in Guatemala and oncology navigator at Dana-Farber/Brigham and Women’s Cancer Center.

This infographic illustrates key findings from the first-of-its-kind study to examine outcomes, evaluate analytics, identify barriers/challenges, analyze performance improvement processes, and identify opportunities for future research.

Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, and Tricia Strusowski, RN, MS, recapped their recent presentation from the ACCC 46th Annual Meeting & Cancer Center Business Summit, in which they discussed the National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstrate Value and Sustainability of Navigation Programs. The study was launched in June 2018 as a collaborative effort between the Academy of Oncology Nurse & Patient Navigators (AONN+), Chartis Oncology Solutions, and the American Cancer Society (ACS).

This May 14-17, our navigation community will gather in Baltimore, MD, for the Academy of Oncology Nurse & Patient Navigators (AONN+) Midyear Conference. And it just wouldn’t be the same without you!

Researchers and clinicians have sought the best ways to implement survivorship care plans (SCPs) after cancer treatment. Despite the strong consensus-based recommendation by the Institute of Medicine and other influential stakeholders, limited evaluation data continue to be a barrier to successful implementation of the guideline.

“Where a woman lives should not determine whether she lives.”